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Abstract
Background: The generalized T-cell activation characterizing HIV-1 and SIVmac infections in
humans and macaques (MACs) is not found in the non-pathogenic SIVagm infection in African green
monkeys (AGMs). We have previously shown that TGF-β1, Foxp3 and IL-10 are induced very early
after SIVagm infection. In SIVmac-infected MACs, plasma TGF-β1 induction persists during primary
infection [1]. We raised the hypothesis that MACs are unable to respond to TGF-β1 and thus
cannot resorb virus-driven inflammation. We therefore compared the very early expression
dynamics of pro- and anti-inflammatory markers as well as of factors involved in the TGF-β1
signaling pathway in SIV-infected AGMs and MACs.
Methods : Levels of transcripts encoding for pro- and anti-inflammatory markers (tnf-α, ifn-γ, il-10,
t-bet, gata-3) as well as for TGF-β1 signaling mediators (smad3, smad4, smad7) were followed by
real time PCR in a prospective study enrolling 6 AGMs and 6 MACs.
Results : During primary SIVmac infection, up-regulations of tnf-α, ifn-γ and t-bet responses (days
1–16 p.i.) were stronger whereas il-10 response was delayed (4th week p.i.) compared to SIVagm
infection. Up-regulation of smad7 (days 3–8 p.i.), a cellular mediator inhibiting the TGF-β1 signaling
cascade, characterized SIV-infected MACs. In AGMs, we found increases of gata-3 but not t-bet, a
longer lasting up-regulation of smad4 (days 1–21 p.i), a mediator enhancing TGF-β1 signaling, and
no smad7 up-regulations.
Conclusion : Our data suggest that the inability to resorb virus-driven inflammation and activation
during the pathogenic HIV-1/SIVmac infections is associated with an unresponsiveness to TGF-β1.
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Background
Progression to AIDS during HIV-1 infection is linked
directly to generalized T cell activation, but only indirectly
to viral load (VL) [2,3]. Moreover, increased T cell activa-
tion levels from the initial stage of infection have a predic-
tive value for AIDS progression even before
seroconversion [4,5]. The precise mechanisms leading to
the aberrant chronic T-cell activation in HIV-1 infection
remain unclear. The study of acute SIV infections in non-
human primate models contributes to the understanding
of the early virus/host interactions. SIVmac infection in
macaques (MACs) best reflects HIV infection in humans.
In contrast, SIV infections in natural hosts of SIV, such as
African Green monkeys (AGMs), are generally non-patho-
genic. During SIVagm infection in AGMs, plasma VLs are
similar to those recorded for pathogenic HIV-1/SIVmac
infections [6] and SIVagm replicates in lymphoid tissues,
including the gut [6,7]. Despite high VLs, natural carriers
Dynamics of pro- and anti-inflammatory markers in PBMC during pathogenic and non-pathogenic SIV infections Figure 1
Dynamics of pro- and anti-inflammatory markers in PBMC during pathogenic and non-pathogenic SIV infec-
tions. A. Tnf-α, ifn-γ and il-10 expressions. B. T-bet and gata-3 expressions. Upper and lower panels represent data from 6 SIV-
mac-infected rhesus MACs and from 6 SIVagm-infected AGMs, respectively. Relative transcript levels are represented by box 
plots in a log scale. BI indicates the baseline before infection (n = 42 corresponding to 7 time points for each of the 6 animals) 
and the following boxes present the gene expression after infection (n = 6 per box). The top and the bottom of the boxes rep-
resent the 75th and 25th percentiles, respectively, whereas the horizontal line between the box limits represent the median. 
Open circles indicate individual values which are not included between the 90th and 10th percentiles. Dark and light grey boxes 
indicate significant (p < 0.05) increases and decreases, respectively, relative to the baseline. Stars indicate a trend towards sig-
nificant up-regulation (p < 0.08). The data on AGMs (tnf-α, ifn-γ and il-10) were previously published [1]. The latter are dis-
played here in a log scale to allow easy and direct comparisons with the data obtained for the pathogenic SIVmac infection.
t
n
f
-
α
α
α
α
i
f
n
-
γ
γ
γ
γ
Relative expression
i
l
-
1
0
MAC AGM
BI
1
3
6
8
10
13
16
21
28
1
0
-
3
1
0
-
2
1
0
-
1
1
1
0
1
1
0
2
1
0
3
1
0
4
1
0
-
3
1
0
-
2
1
0
-
1
1
1
0
1
1
0
2
1
0
3
1
0
4
BI
1
3
6
8
10
13/16
21
28
BI
1
3
6
8
10
13
16
21
28
BI
1
3
6
8
10
13/16
21
28
BI
1
3
6
8
10
13
16
21
28
A
.
B
.
BI
1
3
6
8
10
13/16
21
28
t
-
b
e
t
g
a
t
a
-
3
MAC AGM
Relative expression
1
0
-
3
1
0
-
2
1
0
-
1
1
1
0
1
1
0
2
1
0
3
1
0
4
1
0
-
3
1
0
-
2
1
0
-
1
1
1
0
1
1
0
2
1
0
3
1
0
4
BI
1
3
6
8
10
13
16
21
28
BI
1
3
6
8
10
13/16
21
28
BI
1
3
6
8
10
13
16
21
28
BI
1
3
6
8
10
13/16
21
28
*
*Retrovirology 2006, 3:37 http://www.retrovirology.com/content/3/1/37
Page 3 of 6
(page number not for citation purposes)
of SIV do not show increased lymphocyte activation pro-
files during chronic infection [8]. Our recent data indicate
that AGMs are capable of controling T cell activation rap-
idly after SIVagm infection. This control was associated
with the immediate induction of an anti-inflammatory
environment [1], including an immediate burst of plasma
TGF-β1 [1]. Surprisingly, plasma TGF-β1 was detectable
for longer periods of time in SIVmac-infected MACs [1].
Elevated levels of plasma TGF-β1 were also reported in
HIV+ patients with chronic, progressive infection [9,10].
TGF-β1 is known to mediate negative regulation of
inflammation. We raise the hypothesis that the early burst
of TGF-β1 down-modulates inflammation in AGMs,
whereas the long lasting plasma TGF-β1 levels reflect the
inability of MACs and humans to resorb virus-driven
inflammation and activation [1], perhaps because HIV/
SIVmac infections would render cells unresponsive to
TGF-β1. Therefore we searched for differences between
SIV-infected AGMs and MACs at the levels of molecules
which mediate the ability to respond to TGF-β1. We
found significant differences in the expression levels of
activating and inhibitory mediators of the TGF-β1 signal-
ing pathway between pathogenic and non-pathogenic SIV
infections.
Methods
Six Chinese rhesus macaques (M. mulatta) and 6 AGMs
(C. sabaeus from Senegal) were infected intravenously
with SIVmac251 and SIVagm.sab92018, respectively [1].
The Central Committee for Animals at Institut Pasteur,
Paris, France and the Committee for Ethics and Animal
Experimentation at the International School of Science
and Veterinary Medicine in Dakar, Senegal, reviewed and
approved the use and animals care. This study was con-
ducted on the same animals for which we previously
assessed plasma IL-10 and TGF-β1 (active and latent)
responses [1]. To get a robust baseline, peripheral blood
mononuclear cells (PBMC) were harvested 7 times in each
animal before infection with the same sampling schedule
as used after infection between days 1 to 13 p.i. PBMC iso-
lation, total RNA extraction from PBMC and reverse tran-
scription were previously described [1]. Quantification of
t-bet, gata-3, smad3, smad4 and smad7 transcripts was per-
formed by using Taqman gene expression assays devel-
oped by Applied Biosystems. The references of those
assays are Hs00203436_m1, Hs00231122_m1,
Hs00706299_s1, Hs00232068_m1 and
Hs00178696_m1, respectively. Primers and probes were
previously described for tnf-α,  ifn-γ  and  il-10  [1]. The
expression of each gene was normalized against the
expression of 18S rRNA used as an endogenous control
[1,11]. For each marker, the value at each time point after
infection was compared to the individual baseline before
infection (Statview, Wilcoxon signed-rank test) [1].
Results
We quantified the expression profiles of pro- and anti-
inflammatory factors (tnf-α, ifn-γ and il-10) starting from
24 h after SIVmac infection. We compared them to those
in non-pathogenic SIVagm infection, at the same time
points using the same tools. Significant tnf-α up-regula-
tions in MACs' PBMC were detected from days (d) 3 to 10
and at d28 p.i. (p ≤ 0.046). Ifn-γ gene up-regulations were
observed from d1 to d16 p.i. (p ≤ 0.021) (Figure 1A, upper
panels). In contrast, the il-10 gene expression was signifi-
cantly down-regulated during the first 2 weeks p.i. (p ≤
0.025) and was significantly up-regulated only at day 28
p.i. (p = 0.0003). This is in line with the previously
reported profile of IL-10 concentrations in plasma from
the same animals [1] and with the report of maximal
increase of IL-10+ cells in lymph nodes at day 28 p.i. [12].
SIV-infected AGMs exhibited no tnf-α increase, a later and
more transient ifn-γ up-regulation (d10-16 p.i.), and an
earlier upregulation of il-10 expression (d6-16 p.i.) as pre-
viously reported [1] (Figure 1A, lower panels). These data
confirm a distinct early pro- and anti-inflammatory bal-
ance between these pathogenic and non-pathogenic SIV
infections.
In order to search for further early differences, we quanti-
fied the transcript levels of t-bet and gata-3, which encode
for essential transcription factors for the commitment
towards Th1 and Th2 responses, respectively [13,14].
PBMC of SIVmac-infected MACs displayed significant
increases of t-bet at d3-10 and 28 p.i. (p ≤ 0.017), whereas
SIVagm-infected AGMs displayed either no change or
even decreases in t-bet (d1, d6 p.i.), (p ≤ 0.044) (Figure
1B). Regarding gata-3 expression, we observed significant
increases during both SIVmac and SIVagm infections (p ≤
0.027). The difference between these both infections con-
sisted in the lack of induction of Th1-associated transcrip-
tion factor in AGMs.
The expression of T-bet is known to be suppressed by TGF-
β1 [15]. The latter plays indeed a major role in the nega-
tive regulation of inflammation. To assess whether AGMs
and MACs might differ in their capacity to respond to
TGF-β1, we analysed the expression of Smads which are
the major established intracellular effectors of the TGF-β1
signaling pathway [16]. They comprise three subgroups:
receptor-regulated Smads, common Smads and inhibitory
Smads. We measured the gene expression of one Smad
from each group, respectively, smad3, smad4 and smad7.
Smad3 and 4 are known to activate the TGF-β1 signaling
cascade whereas Smad7 inhibits the TGF-β1 signaling. We
detected an up-regulation of smad3 starting from d1 p.i.
until the 3rd week p.i. in both models (p ≤ 0.008) (Figure
2). In contrast, smad4 up-regulation was more transient in
MACs (p ≤ 0.0023) than in AGMs (p ≤ 0.028), where it
persisted for 3 weeks (Figure 2). Smad7 was up-regulatedRetrovirology 2006, 3:37 http://www.retrovirology.com/content/3/1/37
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during primary SIVmac infection at d1-8 and 28 p.i. (p ≤
0.026) (Figure 2). In contrast, AGMs did not display any
increase and even exhibited a significant decrease of
smad7 expression at d28 p.i. (p = 0.004).
Discussion
These data confirm that the early cytokine balance is dif-
ferent between pathogenic SIVmac251 and non-patho-
genic SIVagm.sab infections: more towards inflammatory
responses in the former and more towards anti-inflamma-
tory responses in the latter. Our data on Smads suggest
that after SIV infection, AGMs are able to respond to TGF-
β1 whereas MACs cannot, due to the up-regulation of
smad7 gene expression and to the lack of sustained up-reg-
ulation of smad4  compared to the AGMs. This might
explain why AGMs are more able to rapidly control the
virus-driven inflammation/activation than MACs.
Mice suffering from inflammatory bowel disease (IBD)
caused by an infectious agent, Toxoplasma gondii, display
up-regulations of smad7  and  t-bet  gene expressions in
CD4+ T cells from the lamina propria [17]. Overexpression
of Smad7 and unresponsiveness to TGF-β1 also character-
ized lamina propria mononuclear cells in gut from patients
suffering from Crohn's disease [18]. Here our study
reports such increases of t-bet and smad7 during acute SIV-
mac infection in MACs but interestingly not during acute
SIVagm infection in AGMs. This may be relevant for HIV
infection, where the intestinal mucosal system is an early
major viral target [19], and where expression of inflam-
matory factors correlates with disease progression [20].
The increase of smad7 in SIVmac-infected MACs might
take place in infected cells and/or be due to indirect mech-
anisms, such as the strong induction of ifn-γ  which is
known to act as a positive regulator of smad7 gene expres-
sion [21]. Ifn-γ is more increased in early SIVmac infection
than in SIVagm infection. SIVmac itself might dysregulate
the TGF-β1 signaling cascade by interacting directly or
indirectly with Smad molecules. Indeed, HCV and HTLV-
1, which also mediate chronic viral infections, were
reported to do so [22-25]. For instance, the HTLV-1 Tax
protein is able to abrogate interactions of Smad3 and
Smad4 with cellular transcription factors [22,24,25].
Dynamics of smad3, smad4 and smad7 expressions in PBMC during pathogenic and non-pathogenic SIV infections Figure 2
Dynamics of smad3, smad4 and smad7 expressions in PBMC during pathogenic and non-pathogenic SIV infec-
tions. See legend in Figure 1.
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TGF-β1 can negatively regulate activation through Treg
induction [26-28], among other mechanisms. Recent
studies have highlighted the important role of TGF-β1
responsiveness not only for the induction and stabiliza-
tion of regulatory activity of CD4+CD25+ Treg but also for
the capacity of other cells to respond to CD4+CD25+ Treg
activity [14,26-29]. In a model of IBD in mice, conven-
tional activated T cells which do not respond to TGF-β are
not controlled by functional Foxp3+ Treg and a dramatic
accumulation of activated IFN-γ+CD4+ T cells is observed
in the gut [29]. HTLV-1+ patients suffering from tropical
spastic paraparesis have decreased frequencies of
Foxp3+CD4+CD25+ Treg as well as impaired Treg func-
tions [30,31]. It is so far unclear if this impairment of Treg
function is due to the ability of Tax to inhibit the TGF-β1
signaling cascade.
The role of Treg during HIV/SIV infections is still contro-
versial. Some studies propose a negative effect of Treg as
they suppress effector T cell responses [12,32-34]. Others
provide evidence associating Treg with a favorable out-
come of the infection and suggest that they are beneficial
by preventing harmful generalized T cell activation [1,35-
38]. In HIV/SIVmac infections, high VL in lymphoid tis-
sues is associated with chronic and generalized T cell acti-
vation. HIV-1+ patients exhibit accumulation of Foxp3+
Treg in tonsils in correlation with their viral load [33].
SIVmac-infected MACs display in their lymph nodes (LN)
an increase of TGF-β1+Foxp3+CD25+CD4+ cell numbers
(d7-d28 p.i.) concomitantly with an elevation of VL [12].
These putative CD4+ Treg are however not capable of lim-
iting the massive T cell hyperactivation in LN [12]. It was
suggested that HIV-specific CD25+ Treg cell function is
compromised relatively early in HIV disease [37]. The Treg
functions and/or the capacity of conventional activated T
cells to respond to TGF-β1 (i) may vary between progres-
sors and long-term non-progressors after HIV/SIVmac
infections and (ii) could contribute to the balance
between HIV-specific effector responses and harmful gen-
eralized T cell activation. In the future, it will be important
to study the capacity of conventional activated T cells and
of Foxp3+Treg from HIV-infected individuals to respond
to TGF-β1. The capacity to respond to TGF-β1 might be an
important determinant, among others virus-host determi-
nants, i.e. the level of Nef-mediated downregulation of
CD3 [39] or the levels of Siglec expression [40], for the
levels of T cell activation and thus for the outcome of HIV/
SIV infections.
To conclude, in response to SIV infection, our study
reveals increases of smad7 expression in MACs as com-
pared to AGMs. The latter retain longer lasting smad4
expression, in conjunction with earlier TGF-β1 and IL-10
induction. Our study suggests that differences in the
capacity to control harmful inflammation in non-patho-
genic and pathogenic infections are associated with differ-
ences in the early activation or inhibition of the TGF-β1
signaling pathway.
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